专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023081959A1 IMMUNOTHERAPEUTIC PROTEINS COMPRISING AN FC REGION COMPONENT WITH A MUTATION AT POSITION 429 审中-公开
公开(公告)号：WO2023081959A1
公开(公告)日：2023-05-19
申请号：PCT/AU2022/051287
申请日：2022-10-26
申请人： THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD
发明人： HOGARTH, Phillip Mark , WINES, Bruce David
IPC分类号： C07K16/46 , C07K19/00 , C12N9/48
摘要： An immunotherapeutic protein and methods of use and production thereof are disclosed, wherein the immunotherapeutic protein comprises one or more immunoglobulin heavy chain polypeptide comprising an Fc region component comprising at least a constant heavy chain domain 3 (CH3) domain (or at least a constant heavy domain 4 (CH4) domain), wherein said one or more polypeptide includes an amino acid substitution at a position corresponding to H429 of the amino acid sequence of human IgG1 heavy chain (Eu numbering) such as H429Y and H429F. The immunotherapeutic protein may be in the form of, for example, an antibody, antibody-like molecule or fusion protein. The amino acid substitution may have the effect of enabling the immunotherapeutic protein to oligomerise (eg into a hexameric form) either in solution or upon binding to a relevant target.

2. 发明申请

WO2014071455A1 DIAGNOSTIC, PROGNOSTIC, THERAPEUTIC AND SCREENING PROTOCOLS WITH RESPECT TO INFECTIOUS MYCOBACTERIUM 审中-公开
标题翻译：关于感染性MYCOBACTERIUM的诊断，预防，治疗和筛选协议
公开(公告)号：WO2014071455A1
公开(公告)日：2014-05-15
申请号：PCT/AU2013/001290
申请日：2013-11-08
申请人： THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD
发明人： ANDERSON, David, Andrew , HANAFIAH, Khayriyyah, Mohd , GARCIA, Mary, Louise , BARNES, Nadine, Carmel , LIU, Joy, Ji , LIESCHKE, Katherine, Rosalind
IPC分类号： G01N33/569
CPC分类号： G01N33/5695
摘要： A diagnostic process for detecting the TB status of a test subject, the process comprising contacting a biological sample comprising antibodies from the subject with a dIgA binding agent, or two or three specific antibody binding agents selected from IgA, IgG and dIgA-binding agents, to allow formation of test complexes between TB antigen specific antibody and antibody binding agent, and measuring the level of each test complex and comparing the level of the test complexes formed to corresponding levels formed in control samples, wherein the levels of at least two test complexes are substantially independent and contribute to enhancing the diagnostic power of the process.
摘要翻译：一种用于检测受试者的结核状态的诊断方法，所述方法包括使包含来自受试者的抗体的生物样品与dIgA结合剂或选自IgA，IgG和dIgA结合剂的两种或三种特异性抗体结合剂接触，以在TB抗原特异性抗体和抗体结合剂之间形成测试复合物，并测量每个测试复合物的水平，并比较形成的测试复合物的水平与对照样品中形成的相应水平，其中至少两个测试复合物是基本独立的，有助于提高过程的诊断力。

3. 发明申请

WO2010148434A1 CHIMERIC MOLECULES 审中-公开
标题翻译： CHIMERIC分子
公开(公告)号：WO2010148434A1
公开(公告)日：2010-12-29
申请号：PCT/AU2010/000775
申请日：2010-06-22
申请人： THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD , GRGACIC, Elizabeth
发明人： GRGACIC, Elizabeth
IPC分类号： C07K14/15 , A61K39/00 , A61K39/145 , A61K39/21 , A61P31/12 , A61P37/04 , C07K14/11 , C07K14/16 , C07K14/18
CPC分类号： C12N7/00 , A61K39/12 , A61K39/145 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , A61K2039/55505 , C07K2319/00 , C12N2740/16134 , C12N2740/17023 , C12N2740/17034 , C12N2760/16122 , C12N2760/16134 , Y02A50/386 , Y02A50/41 , Y02A50/412 , Y02A50/414
摘要： The invention relates to chimeric proteins comprising an antigen and a trimer forming portion or a trimer and virus-like particle forming portion of foamy virus envelope protein (FV TM). The trimer or trimer and virus-like particle forming portion comprises i) full length foamy virus transmembrane protein; ii) foamy virus transmembrane protein absent a functional cytoplasmic domain; iii) foamy virus transmembrane protein absent a functional cytoplasmic domain and transmembrane domain; iv) foamy virus ectodomain comprising N-terminal heptad repeat region and cysteine rich region between N-terminal heptad repeat region and C-terminal α-helical region; v) N-terminal heptad repeat region; vi) a functional variant of any one of i) to v); or vii) any one of i) to vi) lacking an FV fusion peptide domain. In particular, the antigen is an antigen of a virus envelope protein, such as HIV gp120. Soluble and membrane bound forms of trimeric and higher oligomeric forms of the chimeric proteins are provided as well as nucleic acid molecules encoding and expressing same, viral-like particles comprising same, compositions including pharmaceutical compositions, host cells and kits. Methods are described for producing immune responses including antibodies determined by the chimeric protein or VLP, as well as methods of screening using the chimeric protein, VLP and/or antibodies.
摘要翻译：本发明涉及包含抗原和三聚体形成部分或形成泡沫病毒包膜蛋白（FV TM）的三聚体和病毒样颗粒形成部分的嵌合蛋白。三聚体或三聚体和病毒样颗粒形成部分包括i）全长泡沫病毒跨膜蛋白; ii）泡沫病毒跨膜蛋白不存在功能性细胞质结构域; iii）泡沫病毒跨膜蛋白没有功能性细胞质结构域和跨膜结构域; iv）包含N-末端七肽重复区和N末端七重复区和C末端α-螺旋区之间的富含半胱氨酸区的泡沫病毒胞外域; v）N-末端七肽重复区; vi）i）至v）中任一项的功能变体; 或vii）i）至vi）中的任何一个缺乏FV融合肽结构域。特别地，抗原是病毒包膜蛋白的抗原，例如HIV gp120。提供嵌合蛋白质的三聚体和更高级寡聚体形式的可溶性和膜结合形式以及编码和表达嵌合蛋白的核酸分子，包含其的病毒样颗粒，包含药物组合物，宿主细胞和试剂盒的组合物。描述了用于产生包括由嵌合蛋白或VLP测定的抗体的免疫应答的方法，以及使用嵌合蛋白，VLP和/或抗体进行筛选的方法。

4. 发明申请

WO2008037033A1 FLU VACCINE ADMIXTURE OF MANNAN AND FLU ANTIGEN 审中-公开
标题翻译：流行性感冒的流行性感冒
公开(公告)号：WO2008037033A1
公开(公告)日：2008-04-03
申请号：PCT/AU2007/001460
申请日：2007-10-02
申请人： THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED , PIETERSZ, Geoffrey, Allan , ESPARON, Sandra, Elizabeth , PROUDFOOT, Owen
发明人： PIETERSZ, Geoffrey, Allan , ESPARON, Sandra, Elizabeth , PROUDFOOT, Owen
IPC分类号： A61K35/76 , A61P31/16
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5252 , A61K2039/543 , A61K2039/55511 , A61K2039/55583 , C12N2760/16134
摘要： The present invention relates to a vaccine composition comprising a carbohydrate polymer comprising mannose and flu antigen(s) (e.g. whole inactivated influenza virus) in admixture, and a method of immunising a subject comprising the step of administering the vaccine composition to a subject.
摘要翻译：本发明涉及一种包含含有甘露糖和流感抗原（例如全灭活流感病毒）的碳水化合物聚合物的混合物的疫苗组合物，以及免疫受试者的方法，所述方法包括向受试者施用疫苗组合物的步骤。

5. 发明申请

WO2022027088A1 LATERAL FLOW DEVICE AND USES THEREOF 审中-公开
公开(公告)号：WO2022027088A1
公开(公告)日：2022-02-10
申请号：PCT/AU2021/050839
申请日：2021-08-02
申请人： THE UNIVERSITY OF MELBOURNE , THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD
发明人： GODFREY, Dale , PURCELL, Damian , GHERARDIN, Nicholas , ANDERSON, David , FULFORD, Tom , VAN, Huy , ZHENG, Shuning
IPC分类号： G01N33/543 , G01N33/566 , G01N33/68 , A61K39/42 , A61P31/12 , C07K16/10 , B01L3/00 , G01N33/569 , G01N33/58 , G01N33/52
摘要： The present disclosure provides a lateral flow assay (LFA) device for detecting neutralising antibodies against SARS-CoV-2 in a biological fluid sample, and uses thereof. The assay uses competition of the neutralising antibodies present in the sample with the ACE2-RBD on the test strip, leading to binding inhibition and decrease in signal intensity in the test region.

6. 发明申请

WO2012016290A1 MODIFIED HEPATITIS C VIRUS PROTEINS 审中-公开
标题翻译：改良型HEPATITIS C病毒蛋白
公开(公告)号：WO2012016290A1
公开(公告)日：2012-02-09
申请号：PCT/AU2011/000991
申请日：2011-08-04
申请人： THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD , DRUMMER, Heidi , POUMBOURIOS, Pantelis , MCCAFFREY, Kathleen
发明人： DRUMMER, Heidi , MCCAFFREY, Kathleen
IPC分类号： A61K39/29 , C12N7/00 , C07K14/02 , C12Q1/70
CPC分类号： C07K14/1833 , A61K39/00 , A61K39/12 , C07K14/005 , C07K16/109 , C07K2317/76 , C12N7/00 , C12N2770/24222 , C12N2770/24261 , C12N2770/24262 , G01N33/56983
摘要： A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof. A method of producing a composition comprising at least 40%, or at least 45%, or at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70% monomelic HCV E2 polypeptide, the method comprising expressing a polypeptide in a host cell and isolating the expressed product, wherein the polypeptide is an HCV E2 polypeptide including a receptor binding variant, and wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597.
摘要翻译：一种组合物，其包含包含受体结合变体的丙型肝炎病毒（HCV）包膜2（E2）多肽，其中所述多肽被修饰为包含：（i）在2,3或4个半胱氨酸突变或破坏的半胱氨酸，所述半胱氨酸选自C452， C486，C569和C597; 并且其中所述多肽通过分子间二硫键相对于没有半胱氨酸修饰的HCV E2多肽而形成基本上更少的多聚体，并且基本上保留CD81结合; 及其各种用途。一种制备包含至少40％，或至少45％，或至少50％，或至少55％，或至少60％，或至少65％，或至少70％单体HCV E2的组合物的方法所述方法包括在宿主细胞中表达多肽并分离所述表达的产物，其中所述多肽是包含受体结合变体的HCV E2多肽，并且其中所述多肽被修饰为包含：（i）在所述多肽中突变或破坏的半胱氨酸 2,3或4个选自C452，C486，C569和C597的半胱氨酸。

7. 发明申请

WO2008022401A1 RECOMBINANT HCV E2 GLYCOPROTEIN 审中-公开
标题翻译：重组HCV E2 GLYCOPROTEIN
公开(公告)号：WO2008022401A1
公开(公告)日：2008-02-28
申请号：PCT/AU2007/001221
申请日：2007-08-24
申请人： THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED , MC CAFFREY, Kathleen , DRUMMER, Heidi , POUMBOURIOS, Pantelis
发明人： MC CAFFREY, Kathleen , DRUMMER, Heidi , POUMBOURIOS, Pantelis
IPC分类号： C07K14/18 , A61K39/29 , C07K1/36 , A61K35/76 , A61K39/42 , C07K16/08 , A61K38/02 , A61P31/14 , C12P21/08
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/29 , A61K2039/505 , A61K2039/545 , A61K2039/55577 , C07K16/109 , C07K2317/34 , C07K2317/76 , C07K2319/00 , C12N2770/24222 , C12N2770/24234
摘要： The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.
摘要翻译：本发明提供了包含HVR1，HVR2和igVR可变区的HCV-E2受体结合结构域（RBD）的修饰型丙型肝炎病毒（HCV）E2糖蛋白，其中在至少一个所述可变区中至少一部分可变区被柔性接头序列替代。本发明还提供包含修饰的糖蛋白的疫苗组合物及其使用方法。

8. 发明申请

WO2017054033A1 BINDING ASSAYS AND METHOD FOR PROBING ANTIBODY FUNCTION WITH FC BINDING MULTIMERS 审中-公开
标题翻译：用FC绑定多项式检测抗体功能的结合测定和方法
公开(公告)号：WO2017054033A1
公开(公告)日：2017-04-06
申请号：PCT/AU2016/000337
申请日：2016-10-04
申请人： THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD
发明人： HOGARTH, Phillip Mark , WINES, Bruce David
IPC分类号： G01N33/68 , G01N33/53
CPC分类号： G01N33/6854 , G01N33/54306 , G01N33/6845
摘要： The present disclosure relates to the use of an at least one soluble Fc binding multimer comprising at least two Fc binding regions to assess FcR binding activity of an at least one polypeptide comprising an Fc region or fragment thereof, including an antibody, and methods and assays of using the Fc binding multimer to assess FcR binding activity. The FcR binding multimer may be a fusion polypeptide comprising an at least two Fc binding regions, or may consist of at least two peptides each comprising at least one Fc binding region, that are covalently or non-covalently oligomerised.
摘要翻译：本公开涉及包含至少两个Fc结合区的至少一种可溶性Fc结合多聚体的用途，以评估包含Fc区或其片段（包括抗体）的至少一种多肽的FcR结合活性，以及方法和测定使用Fc结合多聚体来评估FcR结合活性。 FcR结合多聚体可以是包含至少两个Fc结合区的融合多肽，或者可以由至少两个各自包含至少一个Fc结合区的共价或非共价低聚的肽组成。

9. 发明申请

WO2012068637A1 COMPOSITIONS AND METHODS 审中-公开
标题翻译：组合物和方法
公开(公告)号：WO2012068637A1
公开(公告)日：2012-05-31
申请号：PCT/AU2011/001534
申请日：2011-11-25
申请人： THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH , DRUMMER, Heidi , MCCAFFREY, Kathleen , POUMBOURIOS, Pantelis
发明人： DRUMMER, Heidi , MCCAFFREY, Kathleen , POUMBOURIOS, Pantelis
IPC分类号： A61K39/29 , A61P31/14 , C07K14/18 , C07K16/10 , G01N33/576
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/55577 , A61K2039/70 , C07K14/005 , C12N2770/24222 , C12N2770/24234 , C12N2770/24271 , G01N33/5767 , G01N2333/186 , G01N2400/02 , G01N2469/20 , G01N2800/52
摘要： The present invention provides a composition comprising hepatitis C virus (HCV) Envelope 2 (E2) glycoprotein, wherein the HCV E2 is substantially monomer depleted HCV E2. Also provide are methods of inducing an HCV immune response.
摘要翻译：本发明提供包含丙型肝炎病毒（HCV）包膜2（E2）糖蛋白的组合物，其中HCV E2基本上是单体耗尽的HCV E2。还提供诱导HCV免疫应答的方法。

10. 发明申请

WO2003063869A1 ANTI-VIRAL COMPOUNDS 审中-公开
标题翻译：反虚构化合物
公开(公告)号：WO2003063869A1
公开(公告)日：2003-08-07
申请号：PCT/AU2003/000093
申请日：2003-01-30
申请人： THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED , ANDERSON, David, Andrew , GAZINA, Elena, Vladimirovna
发明人： ANDERSON, David, Andrew , GAZINA, Elena, Vladimirovna
IPC分类号： A61K31/485
CPC分类号： A61K45/06 , A61K31/485 , A61K31/52 , A61K38/21 , A61K2300/00
摘要： The present invention relates generally to compounds useful in the amelioration of symptoms associated with viral infection. More particularly, the present invention relates to the use of compounds which exhibit a physiological effect on membranous and/or transmembranous structures on or in a cell and which directly or indirectly reduce or inhibit or otherwise prevent viral infection, processing and/or release from the cell. Even more particularly, the present invention contemplates the use of one or more compounds which modulate at least one host cell ion channel in the prophylaxis, treatment and/or symptomatic relief of viral infection in vertebrate animals and in particular in human subjects. The compounds may be provided alone or in combination with other compounds such as those which block or inhibit or at least impair ion channelling. A preferred embodiment of the present invention is the use of the aforementioned anti-viral compounds in the therapeutic management of vertebrate animals including humans, to prevent, reduce or treat infection by certain species of the Picornaviridae family of viral pathogens such as but not limited to Rhinovirus or Enterovirus species.
摘要翻译：本发明一般涉及可用于改善与病毒感染相关的症状的化合物。更具体地说，本发明涉及在细胞上或细胞中对膜和/或跨膜结构表现出生理作用并且直接或间接地减少或抑制或以其它方式预防病毒感染，加工和/或释放细胞的病毒感染，细胞。更具体地说，本发明考虑使用一种或多种调节至少一种宿主细胞离子通道的化合物来预防，治疗和/或症状缓解脊椎动物，特别是在人类受试者中的病毒感染。化合物可以单独提供或与其它化合物组合提供，例如阻断或抑制或至少损害离子通道的化合物。本发明的优选实施方案是上述抗病毒化合物在包括人类的脊椎动物的治疗性管理中的用途，以预防，减少或治疗某些物种的病毒病原体的微小核糖核酸病毒科家族的感染，鼻病毒或肠病毒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式